Open AccessClinicians’ Feedback on Patient/Carer Experience After Switching of Growth Hormone Treatment in Pediatric Patients During COVID-19
Author(s) -
Joanne Blair,
Kelly Warth,
Yashasvi Suvarna,
Marco Cappa
Publication year - 2021
Publication title -
patient preference and adherence
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.885
H-Index - 48
ISSN - 1177-889X
DOI - 10.2147/ppa.s325914
Subject(s) - medicine , covid-19 , growth hormone , intensive care medicine , hormone , bioinformatics , pediatrics , virology , disease , infectious disease (medical specialty) , biology , outbreak
This study investigated why some clinicians switched growth hormone (GH) brands in pediatric patients with GH-related disorders to Norditropin ® since the start of the COVID-19 pandemic, the clinicians' perceptions of the results, and whether observations from this period of disruption could inform clinical practice in the future.